Jupiter Neurosciences closes $2 million registered direct offering

• Jupiter Neurosciences closed a registered direct offering of 7,142,858 common shares, raising gross proceeds of about $2 million.
• Proceeds extend cash runway to fund the company’s Parkinson’s program, including a planned Phase 2a trial.
• Part of the financing was used to reduce debt, improving the balance sheet and shareholder equity position.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Jupiter Neurosciences Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605211715PRIMZONEFULLFEED9725058) on May 21, 2026, and is solely responsible for the information contained therein.